These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37622176)

  • 1. Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.
    Namløs HM; Khelik K; Nakken S; Vodák D; Hovig E; Myklebost O; Boye K; Meza-Zepeda LA
    Mol Oncol; 2023 Nov; 17(11):2432-2450. PubMed ID: 37622176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
    Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
    PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
    Naito Y; Nishida T; Doi T
    Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.
    Al-Maqrashi Z; Burney IA; Taqi KM; Al-Sawafi Y; Qureshi A; Lakhtakia R; Mehdi I; Al-Bahrani B; Kumar S; Al-Moundhri M
    Sultan Qaboos Univ Med J; 2021 May; 21(2):e237-e243. PubMed ID: 34221471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Therapy of Gastrointestinal Stromal Tumors.
    Rutkowski P; Hompes D
    Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.
    Bleckman RF; Roets E; IJzerman NS; Mohammadi M; Bonenkamp HJJ; Gelderblom H; Mathijssen RHJ; Steeghs N; Reyners AKL; van Etten B
    Eur J Cancer; 2023 Jun; 186():113-121. PubMed ID: 37062209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
    Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
    Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
    Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
    Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
    BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
    Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
    J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 19. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
    Keung EZ; Raut CP; Rutkowski P
    Ann Surg Oncol; 2020 Oct; 27(10):3659-3671. PubMed ID: 32734368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.